LDE225 + Everolimus in Advanced Gastroesophageal Adenocarcinoma

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

November 10, 2014

Primary Completion Date

June 8, 2020

Study Completion Date

June 8, 2020

Conditions
Esophageal Cancer
Interventions
DRUG

Everolimus

Induction and Dose Expansion Phase: 10 mg by mouth daily in a 28 day cycle.

DRUG

LDE 225

"Induction Phase Starting Dose: 400 mg by mouth daily in a 28 day cycle.~Expansion Phase Starting Dose: Maximum tolerated dose from Induction Phase."

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novartis

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER